Qiming Venture Partners

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Artavazd Arumov Ph.D

Principal

Ryan Baker

CFO

Cyrus Chan

Associate

Nan Chen

Principal

Chen Liwen

Associate

David Chu

Partner

Isaac Ciechanover

Partner

Phillip DiGiacomo Ph.D

Principal

Phil DiGiacomo

Principal

Anna French Ph.D

Managing Partner

Yuxin Fu

Associate

Jinda Gao

Principal

Robert Headley

Partner

Maykin Ho

Venture Partner

William Hu

Managing Partner

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Duane Kuang

Managing Partner

Nisa Leung

Managing Partner

Lisa Li

Investor

Dingzheng Li

Vice President

Bin Liu

Associate

Jing Liu

Associate

Chang Liu

Associate

Biao LU

Associate

Shuo Mao

Vice President

Will McConnell

Principal

Mark McDade

Partner

Gary Rieschel

Managing Partner

James Shen

Venture Partner

Motao Sun

Associate

Amy Tang

Venture Partner

Yi Tang

Vice President

Xin Wang

Investor

Shiyu Wang

Partner

Bonnie Wang

Partner

Rachel Wang

Venture Partner

James Wang

Venture Partner

Jing Wu

Partner

Xu Gillian

RMB funds CFO

Kuantai Yeh

Partner

Peter Yin

Principal

Janet Yu

Partner

Oscar Zhang

Principal

Zhang Ao

Executive Director

Zhiyuan Zhou

Investor

Alex Zhou

Managing Partner

Yafeng Zhou

Associate

Zhifeng Zhou

Managing Partner

Yiqing Zhu

Associate

Past deals in Series C

Singular Medical

Series C in 2025
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Pulnovo Medical

Series C in 2025
Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Vivatides Therapeutics

Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.

Umoja Biopharma

Series C in 2025
Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Cornerstone Robotics

Series C in 2025
Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

Bioheng

Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

iMile

Series C in 2024
iMile specializes in logistics and courier services across the Middle East. It caters primarily to e-commerce businesses, offering innovative solutions such as Cash on Delivery with tracking, real-time online tracking, international transport, overseas warehousing, and last-mile delivery.

Duet

Series C in 2024
Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Original Point

Series C in 2024
Original Point focuses on the development of CNC systems with five-axis and multi-axis linkage capabilities.

TandemAI

Series C in 2024
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Dezhen Technology

Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

Yidao Biotechnology

Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Alamar Biosciences

Series C in 2024
Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

DH-Robotics

Series C in 2024
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.

Leapstack

Series C in 2023
Leapstack is an insurance technology company founded in February 2016 and headquartered in Shanghai, with additional offices in Beijing and Nanjing. The company specializes in big data artificial intelligence solutions tailored for commercial insurance providers and social security management agencies. Leapstack develops a data analysis and management platform that enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, and anti-fraud compliance identification. By addressing inefficiencies within the insurance industry, Leapstack aims to improve operational effectiveness and facilitate better decision-making for its clients.

SinoUnited Health

Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.

Prismlab China

Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, and electrical technology with computer software and hardware, alongside photopolymer materials. Prismlab's primary focus is on research and development, manufacturing, and marketing of rapid prototyping machines utilizing stereolithography (SLA) technology. Its innovative products are recognized for their quality and performance, reaching customers in over 50 countries and regions, and have garnered critical acclaim from users around the globe.

Fushoukang

Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Tasogare

Series C in 2022
Tasogare Coffee is a premium coffee brand located in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, ensuring accessibility for its customers. With a commitment to quality, Tasogare Coffee aims to deliver an exceptional coffee experience, appealing to discerning coffee enthusiasts.

Belief Biomed

Series C in 2022
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Eigencomm

Series C in 2022
Eigencomm Ltd. is a Shanghai-based company established in 2017 that specializes in the research, development, and sales of cellular network internet chips. The company focuses on creating turnkey solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. Eigencomm offers standard NB-IoT terminal chips that ensure comprehensive cellular data connectivity and extended standby durations, positioning itself as a key player in the cellular IoT market.

Zhenge Biotech

Series C in 2022
Shanghai ZhenGe Biotechnology Co., Ltd. is a research and development company that specializes in the creation of drugs and protein therapeutics. Founded in 2017 and based in Shanghai, China, the company focuses on various aspects of drug development, including mammalian cell line development, upstream and downstream processing, and formulation development. Zhenge Biotech also offers contract development and manufacturing services, as well as assistance with regulatory filings such as IND and BLA. Additionally, the company provides a research platform for antibody development, transient infection processes, N-Glycosylation, and CAR-T technologies. Through these services, Zhenge Biotech supports the pharmaceutical industry in advancing innovative therapeutic solutions.

Yesmro

Series C in 2022
Yesmro, also known as Yimai Gongpin, is a retailer focused on providing small-business automation parts and industrial supplies. The company operates an e-commerce platform that caters to small- to medium-sized enterprises by offering a wide range of products, including electrical accessories, wires and cables, and industrial control components. Yesmro aims to make the procurement of industrial goods easier and more affordable for small businesses by leveraging technology and data-driven solutions. This commitment enables a broad spectrum of enterprises engaged in technological development to access essential industrial products conveniently and at a lower cost.

Rox Motor

Series C in 2021
ROX Motor is a company dedicated to the development of off-road new energy vehicles, specializing in innovative technologies that enhance smart car capabilities. The firm focuses on research and development in several key areas, including new energy power systems, intelligent cockpit designs, and autonomous driving solutions. By providing advanced product definitions and core intelligence technologies, ROX Motor aims to improve the overall quality of products within the new energy vehicle industry, catering to the growing demand for environmentally friendly and technologically advanced transportation options.

Abogen Biosciences

Series C in 2021
Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. is an authoritative anti-cancer academic platform based in Shanghai, China. The company focuses on addressing the information asymmetry prevalent in the oncology field by fostering long-term collaborations with various well-known hospitals and authoritative institutions both domestically and internationally. Liangyihui operates an online platform that provides comprehensive educational materials related to tumor treatment and oncology. This includes medical cases, conference information, online courses, and research reports, all aimed at offering reliable information and resources for oncologists, cancer researchers, and patients. The platform serves as a vital tool for promoting cancer prevention and treatment, thereby enhancing public awareness and understanding of cancer-related issues.

WeRide

Series C in 2021
Guangzhou WeRide Technology Co., Ltd. specializes in developing autonomous driving technology for level 4 vehicles, including its own hardware solutions that ensure comprehensive sensor coverage. Founded in 2017 and headquartered in Guangzhou, China, WeRide has established research and development centers across several major cities in China, as well as in Silicon Valley. The company has received strategic investments from leading global automotive groups and holds the distinction of being the first startup to obtain driverless test permits in both China and the United States. In November 2019, WeRide launched its first publicly accessible Robotaxi service in Guangzhou, which covers an area of 144 square kilometers and has since integrated with Amap, a popular ride-hailing app in China. The service has completed over 147,000 trips for more than 60,000 passengers within its first year. WeRide's offerings include a range of autonomous vehicles, such as Robotaxis, Robobuses, and Robovans, and the company continues to focus on enhancing safety and efficiency in transportation.

Insilico Medicine

Series C in 2021
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

BrainHealth

Series C in 2021
BrainHealth focuses on the research and development, production, and sales of neurological medical equipment.

Yidao Biotechnology

Series C in 2021
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Tungee

Series C in 2021
Tungee, founded in 2016, specializes in providing intelligent sales solutions for B2B enterprises. By leveraging artificial intelligence and big data, the company has developed a comprehensive sales forecasting platform that encompasses various functions, including lead mining, business opportunity engagement, customer relationship management, and order analysis. Tungee's innovative approach addresses the challenges faced by businesses in identifying, contacting, and managing customers, leading to more efficient acquisition of accurate sales leads and reduced customer acquisition costs. As a leader in the Chinese intelligent sales sector, Tungee has successfully served over 3,000 enterprise clients, including prominent organizations such as Alibaba and China Mobile.

P&R Measurement Technology

Series C in 2021
P&R Measurement Technology Co., Ltd. is a Chinese company specializing in the research, development, and supply of testing and automation solutions. Established in 2011 and headquartered in the Bai Jiao Science and Technology Industrial Park in Zhuhai, the company serves various sectors, including motors, household appliances, consumer electronics, and energy power. It leverages its expertise in engineering signal processing, acoustic and vibration testing, and structural analysis to provide customized and semi-custom engineering testing equipment, data processing tools, and consulting services. P&R Measurement Technology also maintains a presence through subsidiaries in Guangzhou, Suzhou, Hong Kong, and the United States, along with offices in several Chinese cities, including Qingdao, Hefei, Shunde, and Ningde.

SinoUnited Health

Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.

CastBox

Series C in 2021
Founded in 2016, CastBox operates a global spoken audio platform offering personalized recommendations for listeners of podcasts, on-demand radio, and audiobooks. Its application is accessible across mobile devices, desktops, and smart home devices, with offices in Beijing, Hong Kong, and San Francisco.

Matrixport

Series C in 2021
Matrixport is a comprehensive platform offering digital asset services, including trading, investing, leveraging, and secure custody for cryptocurrencies.

Booming Technologies

Series C in 2021
Booming Tech is a cloud-based platform that specializes in game development and virtual reality. It provides tools for creators to design and innovate within virtual environments, catering to various applications, including gaming, industrial simulations, and other immersive experiences. The platform features a robust server architecture that ensures players can engage in real-time, stable interactions regardless of their geographical locations. By focusing on both entertainment and practical applications, Booming Tech supports a diverse range of virtual world creation, enabling users to explore new possibilities in digital interaction.

Fucunbao

Series C in 2021
Fucunbao is a company that develops and operates an online platform focused on providing insurance and medical services, primarily serving rural communities in China. Their application offers solutions for medical management, enabling users to purchase insurance online, set up reimbursement plans, and identify disease types digitally. By leveraging government funding and resources, Fucunbao subsidizes insurance and medical expenses, aiming to reduce poverty stemming from healthcare challenges in these areas.

Newsoara

Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Yuanbao Tech

Series C in 2021
Yuanbao Tech is a technology company specializing in quantitative risk management for network security. It offers enterprises integrated solutions that include risk quantitative assessment and analysis, continuous risk monitoring, and early warning management. Utilizing its proprietary network security risk assessment platform, Yuanbao Tech aims to help clients identify and mitigate cybersecurity risks effectively, thereby reducing the likelihood of security breaches. Through its comprehensive services, the company supports organizations in maintaining a robust cybersecurity posture.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. is an authoritative anti-cancer academic platform based in Shanghai, China. The company focuses on addressing the information asymmetry prevalent in the oncology field by fostering long-term collaborations with various well-known hospitals and authoritative institutions both domestically and internationally. Liangyihui operates an online platform that provides comprehensive educational materials related to tumor treatment and oncology. This includes medical cases, conference information, online courses, and research reports, all aimed at offering reliable information and resources for oncologists, cancer researchers, and patients. The platform serves as a vital tool for promoting cancer prevention and treatment, thereby enhancing public awareness and understanding of cancer-related issues.

Yunji Technology

Series C in 2021
Yunji Technology is a Chinese robotics company specializing in the development and manufacture of service robots. These robots are designed to deliver goods commercially, improving efficiency and reducing costs for clients in industries such as hospitality, luxury retail, and restaurants.

Insight Lifetech

Series C in 2020
Insight Lifetech is a medical technology company focused on developing and manufacturing innovative solutions for the diagnosis and treatment of cardiovascular diseases. The company has established a comprehensive platform that integrates research and development, manufacturing, and commercialization, facilitating collaboration across its operations. This synergy accelerates product development, enhances cost-efficiency, and fosters innovation. Notably, Insight Lifetech developed the first domestic fractional flow reserve (FFR) system in China, which received approval from the National Medical Products Administration. Through its high-quality medical devices and advanced technologies, the company aims to provide reliable precision in cardiovascular diagnosis and therapy, ultimately enabling physicians to save and improve patients' lives.

dMed

Series C in 2020
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Nice Tuan

Series C in 2020
Nice Tuan is an e-commerce platform specializing in fresh produce, beverages, leisure food, and a variety of daily supplies. The company operates a community-focused model, partnering with local residential communities to source products from nearby warehouses and producers. By doing so, Nice Tuan aims to provide comprehensive grocery and household item offerings tailored to the needs of local residents. The platform emphasizes efficiency and convenience, striving to create a well-integrated community e-commerce ecosystem centered on daily groceries and fresh produce.

ZEGOCLOUD

Venture Round in 2020
Shenzhen Zego Technology Co., Ltd. is a company based in Shenzhen, China, that specializes in real-time cloud streaming services for audio and video communications. Founded in 2015, Zego offers a comprehensive platform that supports various functionalities, including one-to-one video calls, live broadcasting, and multi-party video conferencing. The platform also provides services for real-time audio streaming, voice chatrooms, and recording and archiving of events such as bank account openings and interviews. Zego targets enterprise and mobile application developers, focusing on delivering stable and high-quality voice and video services across diverse sectors, including social media, online education, and telemedicine. Additionally, the company provides a software development kit (SDK) to facilitate the integration of its services into other applications.

Broncus Technologies

Series C in 2020
Broncus Technologies is a medical technology company specializing in minimally-invasive devices for treating emphysema and other lung diseases. Its flagship product, Exhale, employs Airway Bypass therapy, potentially the first minimally-invasive treatment for severe homogeneous emphysema. Broncus is currently enrolling patients worldwide in its pivotal EASE Trial.

Petkit

Series C in 2020
Shanghai PETKIT Network Technology Co., Ltd., founded in 2013, specializes in developing and manufacturing innovative pet care products. Based in Shanghai, China, the company offers a diverse range of smart devices designed to enhance the health and well-being of pets. Its product lineup includes smart feeders, antibacterial bowls, drinking fountains, and pet monitoring devices that track activity levels, calorie consumption, and overall health. Additionally, Petkit provides a mobile application that integrates with its smart devices, allowing pet owners to monitor their pets' behaviors and health metrics conveniently. By combining technology with pet care, Petkit aims to simplify pet management for owners while ensuring the welfare of their animals.

Antengene

Series C in 2020
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

Nice Tuan

Series C in 2020
Nice Tuan is an e-commerce platform specializing in fresh produce, beverages, leisure food, and a variety of daily supplies. The company operates a community-focused model, partnering with local residential communities to source products from nearby warehouses and producers. By doing so, Nice Tuan aims to provide comprehensive grocery and household item offerings tailored to the needs of local residents. The platform emphasizes efficiency and convenience, striving to create a well-integrated community e-commerce ecosystem centered on daily groceries and fresh produce.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects users with regulated laboratories for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Headquartered in New York, the company operates nationwide in the U.S., Canada, and Europe.

Pratilipi

Series C in 2020
Pratilipi is a platform that connects readers and writers across India, facilitating the discovery, creation, and sharing of stories, poems, articles, and novels in various Indian languages.

Viewtrix Technology

Series C in 2020
Viewtrix Technology specializes in the development of display driver chips and circuit boards, focusing on enhancing display resolution and color representation across various types of screens, including OLED, LCD, and LED. The company’s technologies are designed to support a range of electronic devices such as mobile phones, tablets, and notebooks. By providing advanced display solutions, Viewtrix Technology enables electronics manufacturers to improve the quality of their products while simultaneously reducing costs.

Yunyinggu

Series C in 2020
Yunyinggu Technology Co., Ltd. is a Chinese start-up focused on the development and promotion of innovative display technologies aimed at enhancing the performance of flat panel displays. The company has created a proprietary solution recognized for achieving superior pixel density, or high pixels per inch (PPI), which can be utilized across various types of flat panels, including LCD, LED, and OLED displays. By advancing display technology, Yunyinggu seeks to contribute to the evolving landscape of visual performance in consumer electronics.

DiNovA Medtech

Series C in 2020
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.

Shulan Health

Series C in 2020
Shulan Health operates a hospital center focused on enhancing patient well-being through a range of healthcare services. These services include rehabilitation, nutrition, health examinations, and remote consultations, all designed to meet the diverse needs of patients. The facility adheres to accredited international medical standards, ensuring high-quality care. By integrating advanced IT technology, Shulan Health aims to deliver a personalized and holistic healthcare experience, contributing significantly to the overall health outcomes of its patients.

Abbisko Therapeutics

Series C in 2020
Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

Element Science

Series C in 2020
Element Science is a medical device and digital health company that develops wearable technologies to address sudden cardiac death risk in high-risk cardiovascular patients. The company designs a wearable cardioverter defibrillator and a digital platform that combines patient-centric human factors, machine learning, and rigorous electromechanical medical device development standards. Its solutions support patients transitioning from hospital to home, providing continuous protection during daily activities such as showering and sleeping. Founded in 2011 and headquartered in San Francisco, Element Science aims to reduce avoidable mortality from heart disease through integrated sensing, analytics, and lifesaving therapy delivered via wearable technology.

IntoCare

Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Jacobio Pharmaceuticals

Series C in 2020
Founded in Beijing, China in 2015, Jacobio Pharmaceuticals is a clinical-stage biotech company dedicated to developing innovative drugs for unmet needs in cancer treatment. With a team of over 100 employees and capabilities spanning target discovery to registration, the company has built a robust pipeline of assets with clear competitive advantages.

DST Car

Series C in 2020
DiShangTie Car Rental (Shenzhen) Co., Ltd. is a company based in Shenzhen, China, specializing in the rental and maintenance of commercial electric vehicles (EVs) for passenger and cargo transportation. Established in 2015, the company focuses on the transportation and logistics sector, providing sustainable energy vehicle rental services tailored for the new energy logistics market. DiShangTie also manufactures electric car charging stations, supporting its commitment to offering green and sustainable vehicle leasing alternatives to major express logistics and urban distribution companies. Through its services, the company aims to facilitate the adoption of environmentally friendly transport solutions in China.

Shanghai Kechow Pharma

Series C in 2019
Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

DiNovA Medtech

Series C in 2019
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.

SinoUnited Health

Series C in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopedics, and neurology services. Established in 2004, the center offers a wide range of treatments, including services for foot and ankle issues, acupuncture, chronic pain, movement disorders, migraines, tremors, electromyography, balance training, home exercise programs, manual therapy, post-stroke care, post-herpetic neuralgia, osteoarthritis, and carpal tunnel syndrome. Known for its commitment to high-quality patient care, SinoUnited Health integrates thoughtful design with international standards to enhance the patient experience. The center has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, ensuring high levels of customer satisfaction among both local residents and visitors.

NEIWAI

Series C in 2019
NEIWAI is a mid-to-high-end underwear brand founded in Shanghai in 2012, dedicated to providing comfortable clothing that respects the feelings of women. The company emphasizes a design philosophy that harmonizes comfort, function, and beauty, resulting in a diverse range of products suitable for various daily activities, including home and sports. Over the past five years, NEIWAI has served more than 200,000 female customers, reflecting its commitment to meeting the needs of its clientele. By focusing on the comfort of close-fitting clothing, NEIWAI aims to enhance the everyday experiences of its customers through thoughtfully designed underwear.

Yunyinggu

Series C in 2019
Yunyinggu Technology Co., Ltd. is a Chinese start-up focused on the development and promotion of innovative display technologies aimed at enhancing the performance of flat panel displays. The company has created a proprietary solution recognized for achieving superior pixel density, or high pixels per inch (PPI), which can be utilized across various types of flat panels, including LCD, LED, and OLED displays. By advancing display technology, Yunyinggu seeks to contribute to the evolving landscape of visual performance in consumer electronics.

Amphivena Therapeutics

Series C in 2019
Amphivena Therapeutics, Inc. is a clinical-stage immuno-oncology company based in South San Francisco, California, dedicated to developing bifunctional antibody therapies for hematologic malignancies. Founded in 2012, the company focuses on eradicating blood cancers by leveraging the patient's immune system to target and destroy tumor cells and their precursors. Amphivena's proprietary ReSTORE platform creates dual-action biologics that not only relieve immune suppression but also activate T cell effector functions in cancer patients. This platform is designed with features such as avid binding, target selectivity, and enhanced safety, and can be further engineered to include solid tumor targeting capabilities. By offering differentiated cancer immunotherapies, Amphivena Therapeutics aims to provide new treatment options for patients who are underserved by existing immunotherapies.

Tisenc

Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology systems and advanced diagnostic solutions. Tisenc focuses on creating automatic chemiluminescent analyzers and supporting diagnostic reagents, which are essential in the field of medical diagnostics and point-of-care testing. With over 16,000 square meters dedicated to research and development labs, a GMP factory, and an instrument manufacturing facility, Tisenc maintains full intellectual property rights for its products and technologies, ensuring independence in its research and production processes.

Hesai Technology

Series C in 2019
Founded in 2014, Hesai Technology specializes in designing and manufacturing LiDAR (Light Detection and Ranging) solutions. Its products facilitate advanced driver assistance systems, autonomous vehicles, and robotics across various industries worldwide.

Huimei Technology

Series C in 2019
Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.

Webuy Group

Series C in 2019
Webuy Group, established in 2017 and headquartered in Hangzhou, China, operates as a community-based e-commerce platform focused on apparel. The company owns several brands, including Shaking Baby and Haoyiku. Webuy Group utilizes a social e-commerce model that connects consumers with brands through WeChat, China's leading social media application. This platform allows merchants to share product links directly within their social networks, facilitating immediate purchases. By leveraging trust built through these networks, Webuy Group enhances customer engagement and offers features such as quick payment settlements and low return rates. Additionally, the company provides ongoing training to support business improvement, helping partner brands manage inventory effectively while enabling individual merchants to reach their customers more efficiently.

Haoyiku

Series C in 2019
Haoyiku is a Hangzhou-based community-based e-commerce platform focused on apparel. Founded in 2017 by Qiangqiang Wu, the company operates a S2b2C model that connects platform, brands, buying agents, and consumers through social networks and the WeChat ecosystem. The platform enables partner brands to off-load inventory and allows individual merchants to sell products to their social networks, offering rapid payment settlement, broad customer reach, a low purchase return rate, and ongoing business training to improve performance.

RedDoorz

Series C in 2019
RedDoorz is an online platform that operates in the budget accommodation sector across Southeast Asia. Founded in 2015 and headquartered in Jakarta, Indonesia, the company provides a marketplace for two-star and three-star hotels, enabling travelers to discover affordable lodging options in key business and tourist destinations. RedDoorz not only assists guests in finding reliable stays but also supports hotel and guest house owners by enhancing their visibility, improving operational efficiency, and offering marketing and technology solutions. The platform standardizes amenities such as free Wi-Fi, clean rooms, comfortable beds, and daily mineral water, ensuring a consistent experience for customers. With a workforce of over 1,000 employees across five countries, RedDoorz has established itself as a significant player in the budget hotel segment, facilitating growth opportunities for its partners while catering to the needs of budget-conscious travelers.

Delta Medical

Series C in 2019
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

WorkTrans

Series C in 2019
WorkTrans is a human resource management software developer based in China. The company offers a platform that supports various training modes and capabilities, enhancing developmental opportunities for its clients. Its software facilitates efficient attendance tracking, mobile scheduling, and unified management, enabling organizations to streamline payroll processing, roster management, recruitment, and training related to attendance. By improving these aspects, WorkTrans aims to enhance recruiting efficiency and overall workforce management for businesses.

New Horizon Health

Series C in 2019
New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

Hesai Technology

Series C in 2019
Founded in 2014, Hesai Technology specializes in designing and manufacturing LiDAR (Light Detection and Ranging) solutions. Its products facilitate advanced driver assistance systems, autonomous vehicles, and robotics across various industries worldwide.

zuzuche.com

Series C in 2019
Zuzuche.com is an online platform based in Guangzhou, China, specializing in car rental services both domestically and internationally. Founded in 2011, the company offers a comprehensive range of services, including online booking for car rentals, scenic spots, and local travel products. Its platform provides users with real-time price comparisons and booking options for various vehicles across more than 200 cities in China. In addition to car rentals, Zuzuche.com offers essential travel-related services such as international driver's license translation, Chinese GPS, and car insurance products, including theft and liability coverage. The platform also facilitates the booking of tickets and hotels, enhancing the travel experience for its users. Available as a mobile application, Zuzuche.com aims to deliver convenient and user-friendly solutions for both leisure and business travel needs.

Insta360

Series C in 2019
Insta360 is a technology company based in Shenzhen that specializes in innovative camera solutions designed to enhance how users capture and share experiences. Established in 2014, the company has emerged as a leader in the 360-degree camera market, offering a range of products tailored for various needs, including professional creators and casual users. Their offerings include lightweight portable cameras, mobile phone attachments, cameras specifically designed for vlogging, and advanced VR cinematic cameras. These products enable high-definition 360-degree photos and videos, allowing users to live-stream their experiences on major social media platforms. Through its commitment to performance and accessibility, Insta360 empowers users to relive and share their moments in immersive detail, particularly when experienced through virtual reality headsets.

Zuiyou

Series C in 2019
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content, including recommendations, topics, and videos. The platform distinguishes itself by decentralizing user comments, presenting them in a non-linear manner rather than prioritizing them based on popularity. This approach encourages diverse interactions and allows users to engage with content in a more organic and personalized way. Through its innovative features, Zuiyou aims to foster a unique community where individuals can connect over shared interests and explore a wide array of topics.

Petkit

Series C in 2019
Shanghai PETKIT Network Technology Co., Ltd., founded in 2013, specializes in developing and manufacturing innovative pet care products. Based in Shanghai, China, the company offers a diverse range of smart devices designed to enhance the health and well-being of pets. Its product lineup includes smart feeders, antibacterial bowls, drinking fountains, and pet monitoring devices that track activity levels, calorie consumption, and overall health. Additionally, Petkit provides a mobile application that integrates with its smart devices, allowing pet owners to monitor their pets' behaviors and health metrics conveniently. By combining technology with pet care, Petkit aims to simplify pet management for owners while ensuring the welfare of their animals.

MicroTech Medical

Series C in 2018
MicroTech Medical, founded in January 2011 in Hangzhou Future Technical City, is a company focused on the research, development, and manufacturing of innovative and affordable medical devices for diabetes care. The firm specializes in creating both treatment and monitoring devices aimed at improving diabetes management, primarily serving the Chinese market while also reaching international customers. With significant backing from Eli Lilly and Company, MicroTech Medical is dedicated to enhancing the quality of life for individuals living with diabetes through advanced technology solutions.

APT Medical

Series C in 2018
APT Medical Inc. is a high-tech enterprise based in Shenzhen, China, specializing in the research, development, manufacture, and sale of minimally invasive interventional medical devices for cardiovascular and cerebrovascular diseases. Founded in 2002, the company offers a range of products, including electrophysiological catheter delivery systems, radiofrequency ablation and mapping catheters, and vascular intervention products, which encompass diagnostic and treatment solutions as well as accessory items. APT Medical also provides original equipment manufacturing (OEM) and original design manufacturing (ODM) services for catheter and metal products. The company operates production facilities in Shenzhen and Hunan, and its products are distributed in various regions, including Europe and Southeast Asia.

Akulaku

Series C in 2018
Akulaku is a Southeast Asia fintech platform that provides online credit and digital financial services. Founded in 2016 and based in Jakarta, Indonesia, it serves customers across Indonesia, the Philippines, and Malaysia with digital banking, digital financing, digital investment, and insurance brokerage offerings. The company operates a virtual credit card and ecommerce platform, as well as Asetku, an online wealth management service, and a mobile neobank supported by Bank Neo Commerce. It focuses on meeting the daily financial needs of underserved customers in emerging markets and aims to reach about 50 million users across Southeast Asia by 2025.

ET Healthcare

Series C in 2018
ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.

SequoiaDB

Series C in 2018
SequoiaDB Corporation is a distributed database company based in Shenzhen, China, founded in 2011. It specializes in developing enterprise-class distributed relational databases, notably SequoiaDB, designed for core online transactions, data center operations, and content management. The company also offers SequoiaCM, an enterprise content management solution that addresses the challenges of storing and managing large volumes of unstructured data for medium and large enterprises. SequoiaDB's suite of products supports various applications, including online transaction businesses and data lake solutions, and it primarily serves clients in the financial sector, such as banks, insurance companies, and securities firms. The company has gained recognition in the database industry for its innovative approach and has been featured in Gartner’s reports as a leading provider of advanced database systems.

Jacobio Pharmaceuticals

Series C in 2018
Founded in Beijing, China in 2015, Jacobio Pharmaceuticals is a clinical-stage biotech company dedicated to developing innovative drugs for unmet needs in cancer treatment. With a team of over 100 employees and capabilities spanning target discovery to registration, the company has built a robust pipeline of assets with clear competitive advantages.

CANbridge Pharmaceuticals

Series C in 2018
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Zuiyou

Series C in 2018
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content, including recommendations, topics, and videos. The platform distinguishes itself by decentralizing user comments, presenting them in a non-linear manner rather than prioritizing them based on popularity. This approach encourages diverse interactions and allows users to engage with content in a more organic and personalized way. Through its innovative features, Zuiyou aims to foster a unique community where individuals can connect over shared interests and explore a wide array of topics.

Moretickets

Series C in 2018
Moretickets is an online ticketing company based in Shanghai that offers a platform for purchasing first-hand performance tickets. The company employs a multi-channel ticket bidding mechanism that eliminates intermediaries, allowing users to access strictly audited tickets at discounted prices. Moretickets provides detailed information about various performances, enabling customers to make informed purchasing decisions while securing tickets at more affordable rates.

Lanjinrong

Series C in 2018
Lanjinrong is a Beijing Based Fintech Start Up.

Bang Er Orthopedic

Series C in 2018
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.

XSKY Data Technology

Series C in 2018
XSKY Data Technology, based in Beijing, specializes in software-defined infrastructure products and services. It offers a range of storage solutions, including XCBS (cloud), XEBS (block), XEUS (unified), XEOS (object), and XEDP (unified data platform), catering to diverse sectors such as finance, telecom, energy, and government. XSKY is a significant contributor to the open-source Ceph storage system, ranking top 3 globally. It partners with leading tech companies like Intel and Samsung, providing scalable, cost-effective storage solutions tailored for enterprise needs.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

Eceyes Internet Financial

Series C in 2018
Eceyes Internet Financial is an insurance technology platform offering insurance and related products.

Miaoshou Doctor

Series C in 2018
Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

Bondent

Series C in 2018
Bondent Technology Co., Ltd., headquartered in Shanghai, China, specializes in supplying dental equipment and materials. It offers a comprehensive range of services, including technical training, operational and management consulting, decoration design, and financial solutions. Bondent's core business involves the design, development, manufacturing, and sales of oral medical equipment, creating a full ecosystem for the dental and oral health industry.

XiaoMan Technology

Series C in 2018
XiaoMan Technology is a foreign trade solutions provider based in Shenzhen, China, established in 2013. The company specializes in developing software-as-a-service (SaaS) business management solutions that leverage big data and artificial intelligence. Its offerings include customer relationship management technology designed to assist enterprises in expanding their international operations. XiaoMan's products and services are characterized by their flexibility and compatibility, catering to both small and micro enterprises as well as larger organizations with specific customization needs. By employing a comprehensive, customer-focused system for research and development, customer service, sales, and marketing, XiaoMan Technology aims to deliver high-quality solutions that enhance customer service, boost sales productivity, and facilitate customer acquisition for its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.